PARP1 and glioma: These adaptation mechanisms may serve as potential target for glioma therapy and suggest that β-oxidation inhibitors and probably lysosomal inhibitors (Figure 5A) may potentiate the effect of PARP inhibition in glioblastoma, and contribute to increased life expectancy in the patients of this malignant disease.